| IFX-20-PRODUCT-CANDIDATE |
IFX-20-PRODUCT-CANDIDATE |
85%
|
The Loan Agreement contains customary events of default, which include the discontinuance of the Company's development program for its IFx-20 product candidate. |
| PARKVIEW-HOLDINGS-ONE-LLC |
PARKVIEW-HOLDINGS-ONE-LLC |
85%
|
The Company granted to Parkview an annual royalty on sales by the Company and its sublicensees of products that incorporate or are based on the Company's intellectual property covering IFx-2.0. |
| ADGERO-BIOPHARMACEUTICALS-HOLDINGS-INC |
ADGERO-BIOPHARMACEUTICALS-HOLDINGS-INC |
62%
|
nancing activities 10,570 1,852 Increase (decrease) in cash and cash equivalents 3,374 ( 10,245 ) Cash and cash equivalents – beginning of year 1,535 11,780 Cash and cash equivalents – end of year 4,… |
| ADGERO-BIOPHARMACEUTICALS-HOLDINGS-INC-ADGERO-BI |
ADGERO-BIOPHARMACEUTICALS-HOLDINGS-INC-ADGERO-BI |
62%
|
of Kineta Inc. (“Kineta”) via merger on June 30, 2025 (the “Kineta Merger”). VISTA (otherwise referred to as V-domain Ig suppressor of T cell activation ) is an immune checkpoint highly expressed on … |
| ADVANZ-PHARMA-HEALTHCARE-CORP |
ADVANZ-PHARMA-HEALTHCARE-CORP |
62%
|
velop will be made on a payor-by-payor basis. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier o… |
| B-C-LTD |
B-C-LTD |
62%
|
nancing activities 10,570 1,852 Increase (decrease) in cash and cash equivalents 3,374 ( 10,245 ) Cash and cash equivalents – beginning of year 1,535 11,780 Cash and cash equivalents – end of year 4,… |
| BERRY-ONLY-INC |
BERRY-ONLY-INC |
62%
|
velop will be made on a payor-by-payor basis. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier o… |
| CMBC-ROGERS-SCIENCES-INC |
CMBC-ROGERS-SCIENCES-INC |
62%
|
velop will be made on a payor-by-payor basis. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier o… |
| CO-LLC |
CO-LLC |
62%
|
g the timing of our preclinical studies and clinical trials and the expenditures related to other research and development activities. We expect to continue to incur operating losses. We anticipate t… |
| COMPANY-HURA-MERGER-SUB-II-LLC |
COMPANY-HURA-MERGER-SUB-II-LLC |
62%
|
indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangibl… |
| COMPANY-HURA-MERGER-SUB-I-INC |
COMPANY-HURA-MERGER-SUB-I-INC |
62%
|
g the timing of our preclinical studies and clinical trials and the expenditures related to other research and development activities. We expect to continue to incur operating losses. We anticipate t… |
| DELMAR-PHARMACEUTICALS-INC |
DELMAR-PHARMACEUTICALS-INC |
62%
|
velop will be made on a payor-by-payor basis. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier o… |
| EQUINITI-TRUST-COMPANY-LLC |
EQUINITI-TRUST-COMPANY-LLC |
62%
|
fective time of the Merger, shares of the Company’s preferred stock were converted into shares of Company common stock and all of the Notes issued by the Company were converted into shares of Company… |
| HURA-MERGER-SUB-II-LLC |
HURA-MERGER-SUB-II-LLC |
62%
|
g the timing of our preclinical studies and clinical trials and the expenditures related to other research and development activities. We expect to continue to incur operating losses. We anticipate t… |
| KINTARA-THERAPEUTICS-INC |
KINTARA-THERAPEUTICS-INC |
62%
|
velop will be made on a payor-by-payor basis. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier o… |
| K-V-INVESTMENT-LLC |
K-V-INVESTMENT-LLC |
62%
|
uding the timing of our preclinical studies and clinical trials and the expenditures related to other research and development activities. We expect to continue to incur operating losses. We anticipa… |
| K-V-INVESTMENT-ONE-LLC |
K-V-INVESTMENT-ONE-LLC |
62%
|
g the timing of our preclinical studies and clinical trials and the expenditures related to other research and development activities. We expect to continue to incur operating losses. We anticipate t… |
| PINNACLE-BIOLOGICS-INC |
PINNACLE-BIOLOGICS-INC |
62%
|
velop will be made on a payor-by-payor basis. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier o… |
| VALENT-TECHNOLOGIES-LLC |
VALENT-TECHNOLOGIES-LLC |
62%
|
of TuHURA common stock. Components of Our Results of Operations Revenue We did not generate any revenue and do not expect to generate any revenue from the sale of products in the near future. Researc… |
